News media coverage of medication research: reporting pharmaceutical company funding and use of generic medication names.

CONTEXT The news media are an important source of information about medical research for patients and even some physicians. Little is known about how frequently news articles report when medication research has received funding from pharmaceutical companies or how frequently news articles use generic vs brand medication names. OBJECTIVES To assess the reporting of pharmaceutical company funding and generic medication name use in news articles about medication studies and to determine the views of newspaper editors about these issues. DESIGN, SETTING, AND PARTICIPANTS We reviewed US news articles from newspaper and online sources about all pharmaceutical company-funded medication studies published in the 5 most prominent general medical journals between April 1, 2004, and April 30, 2008. We also surveyed editors at the 100 most widely circulated newspapers in the United States. MAIN OUTCOME MEASURES The percentage of news articles indicating when studies have been pharmaceutical company-funded and the percentage that refer to medications by their generic vs brand names. Also the percentage of newspaper editors who indicate that their articles report pharmaceutical company funding; the percentage of editors who indicate that their articles refer to medications by generic names; and the percentage of newspapers with policies about these issues. RESULTS Of the 306 news articles about medication research identified,130 (42%; 95% confidence interval [CI], 37%-48%) did not report that the research had received company funding. Of the 277 of these articles reporting on medications with both generic and brand names, 186 (67%; 95% CI, 61%-73%) referred to the study medications by their brand names in at least half of the medication references. Eighty-two of the 93 (88%) newspaper editors who responded to our survey reported that articles from their publications always or often indicated when studies had received company funding (95% CI, 80%-94%), and 71 of 92 (77%) responding editors also reported that articles from their publications always or often referred to medications by the generic names (95% CI, 67%-85%). However, only 3 of 92 newspapers (3%) had written policies stating that company funding sources of medical studies be reported (95% CI 1%-9%), and 2 of 93 (2%) newspapers had written policies stating that medications should be referred to by their generic names (95% CI 1%-8%). CONCLUSION News articles reporting on medication studies often fail to report pharmaceutical company funding and frequently refer to medications by their brand names despite newspaper editors' contention that this is not the case.

[1]  Steven Woloshin,et al.  Press releases: translating research into news. , 2002, JAMA.

[2]  Paul M Ridker,et al.  Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. , 2006, JAMA.

[3]  Joel Lexchin,et al.  Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[4]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[5]  Gary Schwitzer,et al.  How Do US Journalists Cover Treatments, Tests, Products, and Procedures? An Evaluation of 500 Stories , 2008, PLoS medicine.

[6]  S B Soumerai,et al.  Coverage by the news media of the benefits and risks of medications. , 2000, The New England journal of medicine.

[7]  Richard R. Cline,et al.  Exploring Generic Drug Use Behavior: The Role of Prescribers and Pharmacists in the Opportunity for Generic Drug Use and Generic Substitution , 2002, Medical care.

[8]  Vidya Sharma,et al.  Influence of the news media on diagnostic testing in the emergency department. , 2003, Archives of pediatrics & adolescent medicine.

[9]  Jessica S. Ancker,et al.  A comparison of conflict of interest policies at peer-reviewed journals in different scientific disciplines , 2007, Sci. Eng. Ethics.

[10]  Using trade names: a risk factor for accidental drug overdose. , 2002, Archives of internal medicine.

[11]  Michael A. Steinman,et al.  What’s in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice , 2007, Journal of General Internal Medicine.

[12]  L. Kjaergard,et al.  Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ , 2002, BMJ : British Medical Journal.

[13]  T. Caulfield The Commercialisation of Medical and Scientific Reporting , 2004, PLoS medicine.

[14]  B. Thiers Potential Savings From Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000 , 2006 .

[15]  A. Flanagin,et al.  Reporting financial conflicts of interest and relationships between investigators and research sponsors. , 2001, Journal of the American Medical Association (JAMA).

[16]  Gary L. Kreps,et al.  Trust and sources of health information: the impact of the Internet and its implications for health care providers: findings from the first Health Information National Trends Survey. , 2005, Archives of internal medicine.

[17]  R. Cooper,et al.  Conflict of interest disclosure policies and practices in peer-reviewed biomedical journals , 2006, Journal of General Internal Medicine.

[18]  N. Buckley,et al.  XmasTM (brand substitution not permitted) , 2006, The Medical journal of Australia.

[19]  J. Drazen,et al.  Full disclosure and the funding of biomedical research. , 2008, The New England journal of medicine.

[20]  Catherine D DeAngelis,et al.  Impugning the integrity of medical science: the adverse effects of industry influence. , 2008, JAMA.

[21]  S. Chapman,et al.  Can even minimal news coverage influence consumer health-related behaviour? A case study of iodized salt sales, Australia. , 2008, Health education research.

[22]  L. Schwartz,et al.  Translating Research Into News , 2002 .

[23]  Christian Gluud,et al.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? , 2003, JAMA.